AI assistant
Pharmanutra — Interim / Quarterly Report 2026
May 11, 2026
4324_rns_2026-05-11_731418c5-bc8b-481a-bbdb-ccac710fa322.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
teleborsa
| Informazione Regolamentata n. 20106-20-2026 | Data/Ora Inizio Diffusione 11 Maggio 2026 17:35:08 | Euronext Star Milan |
|---|---|---|
Societa': PHARMANUTRA
Utenza - referente : PHARMANUTRAN05 - Simona Del Re
Tipologia : 3.1
Data/Ora Ricezione : 11 Maggio 2026 17:35:08
Oggetto : THE BoD APPROVES THE INTERIM MANAGEMENT REPORT AS OF MARCH 31ST 2026
Testo del comunicato
Vedi allegato
emarket
with storage
CERTIFIED
PHARMANUTRA
PHARMANUTRA S.P.A.:
THE BoD APPROVES THE INTERIM MANAGEMENT REPORT AS OF MARCH 31ST 2026
ANOTHER QUARTER OF DOUBLE-DIGIT GROWTH,
FUELED BY AN EXCELLENT PERFORMANCE OF BOTH DOMESTIC AND INTERNATIONAL MARKETS
- REVENUES AT € 33.4 MILLION, +24.5% VERSUS Q1 2025
- GROSS OPERATING RESULT AT € 6.2 MILLION (+25.8% VERSUS Q1 2025)
- NET RESULT AT € 3.5 MILLION (+41.9% VERSUS Q1 2025)
- CASH FLOW FROM OPERATIONS FOR € 1.9 MILLION
Pisa, May 11th 2026 – The Board of Directors of Pharmanutra S.p.A. (MTA; Ticker PHN), a company specialising in mineral-based nutritional supplements and medical devises for muscles and joints, convened today, approved the unaudited Interim Management Report as at March 31st 2026.
Roberto Lacorte, Vice Chairman and CEO of Pharmanutra S.p.A., commented: "We are pleased to share another significant interim update on the Company's results, with a first quarter that confirms a path of solid, high-quality growth. The results achieved reflect the progressive and tangible effectiveness of the investments made over the past two years in support of the business's main strategic growth drivers. These growth trajectories are also making a meaningful contribution to improved profitability, confirming the soundness of the industrial and strategic choices undertaken. In this context, a particular source of satisfaction is the Company's ability to continue demonstrating resilience, operational continuity and strong performance, despite an international environment marked by persistent geopolitical tensions and increasing market complexity. Once again, therefore, Pharmanutra can look to the future with confidence, relying on solid foundations that support further growth opportunities and new development and expansion initiatives."
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALC ISO 9001
SGS
SGS
FARMINAUTRA
PHARMANUTRA
PHARMANUTRA
PHARMANUTRA
PHARMANUTRA
AKERN
ANALYTICAL
Cetilar
emarket
with storage
CERTIFIED
PHARMANUTRA
CONSOLIDATED RESULTS AS OF MARCH 31ST 2026
| ECONOMIC DATA (€ million) | 2025 | % | 2024 | % | Change |
|---|---|---|---|---|---|
| REVENUES | 33,4 | 100,0% | 26,8 | 100,0% | 24,5% |
| SALES REVENUES | 32,7 | 97,9% | 26,4 | 98,4% | 24,0% |
| EBITDA | 6,2 | 18,6% | 4,9 | 18,4% | 25,8% |
| NET RESULT | 3,5 | 10,3% | 2,4 | 9,1% | 41,9% |
| Earning per Share(Euro) | 0,36 | 0,25 | 42,2% | ||
| BALANCE SHEET & EQUITY (€ million) | 2025 | 2024 | Change | ||
| --- | --- | --- | --- | ||
| NET INVESTED CAPITAL | 62,6 | 59,8 | 2,8 | ||
| NET FINANCIAL POSITION | 11,9 | 11,4 | 0,5 | ||
| EQUITY | (74,5) | (71,2) | 3,2 |
SALES REVENUES AS AT MARCH 31ST 2026
Consolidated net revenues at March 31st 2026 amounted to Euro 32.7 million versus Euro 26.4 million at March 31st 2025, with a 24% increase.
Revenues from the business "As is", that is excluding the new business units, increased both in the Italian market (+15% approximately) and in international markets (+32%). The revenue increase in the domestic market derives from the implementation of the new commercial structure started in January 2026, while the revenue increase from international markets is positively influenced by the order intake dynamics from distributors.
Revenues from the new business units significantly increased versus March 31st 2025 (+108% approximately), in particular for Pharmanutra USA.
Sales volumes of finished products as at March 31st 2026, equal to approximately 3.7 million units, increase by 22% versus March 31st 2025 (3 million units).
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALC ISO 9001
SGS
SGS
FIREPROTECTED SINCE 1914
FORM 9461-2014
CERTIFIED
PHARMANUTRA
group
PHARMANUTRA
PHARMANUTRA
PHARMANUTRA
AKERN
CERTIFIED
Cetilar
CERTIFIED
PHARMANUTRA
| New BU contribution | Incidence | |||||
|---|---|---|---|---|---|---|
| €/1000 | 2026 | 2025 | Δ | Δ% | 2026 | 2025 |
| AS IS Italy Revenues | 19.456 | 16.972 | 2.484 | 14,6% | 59,5% | 64,3% |
| Nutrition Revenues | 385 | 318 | 67 | 21,1% | 1,2% | 1,2% |
| Domestic Market revenues | 19.841 | 17.290 | 2.548 | 14,7% | 60,7% | 65,5% |
| ROW AS IS Revenues | 10.958 | 8.307 | 2.651 | 31,9% | 33,5% | 31,5% |
| New BU ROW revenues | 1.908 | 786 | 1.122 | 142,7% | 5,8% | 3,0% |
| Foreign markets revenues | 12.866 | 9.094 | 3.773 | 41,5% | 39,3% | 34,5% |
| Total AS IS revenues | 30.414 | 25.279 | 5.135 | 20,3% | 93,0% | 95,8% |
| Total New BU revenues | 2.293 | 1.104 | 1.189 | 107,7% | 7,0% | 4,2% |
| Total Revenues | 32.707 | 26.384 | 6.324 | 24,0% | 100% | 100% |
Sales Revenues - Italy
Revenues from the Italian market, equal to Euro 19.8 million (Euro 17.3 million at March 31st 2025) shows a 14.7% increase with a 60.7% incidence on total net revenues versus 65.5% in the same period of last year.
Sales Revenues – Foreign Markets
Revenues from foreign markets amounted to Euro 12.9 million versus Euro 9.1 million at March 31st 2025 with a significant 41.5% increase; incidence on total revenues grew from 34.5% at March 31st 2025 to 39.3% at March 21st 2026.
Europe (excluding Italy) remains the largest contributor to foreign revenues; the contribution from Far East and Nord America increases too, thanks to the sales increase in China (Euro 1.1 million versus Euro 0.7 million at March 31st 2025) and United States (Euro 0.8 million versus Euro 0.1 million).
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALC ISO 9001
SGS
SGS
FIRE PROTECTI ON DELICA CERTIFICATI DELLE POLITICHE CIVILI SISTEMA DI GESTIONE CERTIFICATO
PHARMANUTRA
group
PHARMANUTRA
PHARMANUTRA
PHARMANUTRA
EXPRESS
AKERN
CERTIFIED
Cetilar
CERTIFIED
PHARMANUTRA
| Revenues by geographic area | Incidence | ||||
|---|---|---|---|---|---|
| €/1000 | 2026 | 2025 | Δ% | 2026 | 2025 |
| Italy | 19.841 | 17.290 | 14,8% | 60,7% | 65,5% |
| Total Italy | 19.841 | 17.290 | 14,8% | 60,7% | 65,5% |
| Europe | 5.698 | 4.985 | 14,3% | 17,4% | 18,9% |
| Middle east | 2.571 | 1.990 | 29,2% | 7,9% | 7,5% |
| Far east | 1.450 | 831 | 74,6% | 4,4% | 3,1% |
| North America | 1.205 | 285 | 323,5% | 3,7% | 1,1% |
| South America | 335 | 172 | 94,5% | 1,0% | 0,7% |
| Other | 1.607 | 831 | 93,4% | 4,9% | 3,1% |
| Total Rest of World | 12.866 | 9.094 | 41,5% | 39,3% | 34,5% |
| Total | 32.707 | 26.384 | 24,0% | 100% | 100% |
During the first quarter of 2026, the internationalisation process continued with the contract signing with the French multinational company PiLeje aimed at the distribution of Sideral®Forte and Sideral®Oro in France and Switzerland. The product distribution will start in September 2026, allowing the Group to strengthen its positioning in Europe by covering a strategic market for future development.
SALES REVENUES BY PRODUCT LINE
The revenue analysis by product line shows the strong growth of the Sideral® line (+28.9%), driven by the development in international markets, where it is widely distributed; furthermore, a significant increase was recorded from the Cetilar® line, which achieved 3 million Euro in revenues, with a 20.6% increase versus the same period last year, and from Apportal®, which recorded a 19.7% revenue increase.
| Revenues by Product Line | Incidence | ||||
|---|---|---|---|---|---|
| €/1000 | 2026 | 2025 | Δ% | 2026 | 2025 |
| Sideral | 22.064 | 17.114 | 28,9% | 67,5% | 64,9% |
| Cetilar | 3.003 | 2.490 | 20,6% | 9,2% | 9,4% |
| Apportal | 2.815 | 2.352 | 19,7% | 8,6% | 8,9% |
| Sidevit B12 | 652 | 407 | n.s. | 2,0% | 1,5% |
| Ultramag | 391 | 519 | -24,7% | 1,2% | 2,0% |
| Other | 778 | 713 | 9,2% | 2,4% | 2,7% |
| Medical Instruments | 2.306 | 2.077 | 11,0% | 7,1% | 7,9% |
| Raw Materials | 698 | 711 | -1,8% | 2,1% | 2,7% |
| Total | 32.707 | 26.384 | 24,0% | 100% | 100% |
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmacnutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
AEGI
SGS
SGS
FIRE PROTECTIVE GAS METAL
FREMMENNITRA
SGS
PHARMANUTRA
A
PHARMANUTRA
A
PHARMANUTRA
A
AKERN
CERTIFIED
Cetilar
emarket
with storage
CERTIFIED
PHARMANUTRA
ECONOMIC RESULTS
Gross Operating Result (EBITDA) of Pharmanutra Group reached 6.2 million Euro (+ Euro 1.3 million versus March 31st 2025) with a margin on revenues of 18.6% (18.4% in the same period last year).
Net Result for the period is equal to Euro 3.5 million versus Euro 2.4 million at March 31st 2025.
Net Earnings per Share at March 31st 2026 amounts to Euro 0.36 versus Euro 0.25 in the same period last year.
Net Financial Position at March 31st 2026 is positive for Euro 11.9 million versus Euro 11.4 million at December 31st 2025. Operating activities for the period generated approximately Euro 1.9 million in cash, in line with March 31st, 2025.
SIGNIFICANT EVENTS AFTER MARCH 31ST 2026
No significant events occurred after March 31st 2026.
EXPECTED BUSINESS DEVELOPMENT
Results of the first months of 2026 confirm the revenue growth expectations versus the previous year, both in the Italian and international markets, for the recurring business as well as for the new business units. Thanks to our ability to adapt and remain resilient, we also expect an increase in marginality, which is supposed to progressively grow in the coming years, together with a strong cash generation.
With reference to the current geopolitical situation and related international tensions, we do not foresee significant impacts on our business due to the US/Iran conflict.
The unaudited interim management report at March 31st 2026 will be made available to the public in the manner and within the timeframes provided by the current regulations.
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALC ISO 9001
SGS
SGS
FIRE PROTECTIVE
GESTIONE CERTIFICATO
SISTEMA DI GESTIONE CERTIFICATO
ISO 14001
PHARMANUTRA
group
PHARMANUTRA
PHARMANUTRA
CERTIFIED
AKERN
CERTIFIED
Cetilar
emarket
with storage
CERTIFIED
PHARMANUTRA
CERTIFICATION OF THE MANAGER IN CHARGE OF PREPARING THE FINANCIAL STATEMENTS
The Manager responsible for preparing the company's financial reports, Mr. Francesco Sarti, declares, pursuant to paragraph 2 of Article 154 bis of Legislative Decree 58/1998, that the accounting information contained in this press release corresponds to the documented results and accounting books and records.
FINANCIAL STATEMENTS (UNAUDITED)
Annex 1 - Consolidated Balance Sheet
Annex 2 - Consolidated Income Statement and Consolidated Statement of Comprehensive Income
Annex 3 - Statement of changes in Consolidated Shareholders' Equity
Annex 4 - Consolidated Cash Flow Statement
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALCERTIFIED
S
SGS
SGS
SGS
FARMINDUSTRIA
ASSOCIATION
MEMBER OF
SGS
PHARMANUTRA
PHARMANUTRA
PHARMANUTRA
AKERN
CERTIFIED
Cetilar
CERTIFIED
PHARMANUTRA
Annex 1
CONSOLIDATED BALANCE SHEET
| €/1000 | 31/03/2026 | 31/12/2025 |
|---|---|---|
| NON CURRENT ASSETS | 53.455 | 52.331 |
| Buildings, plant and equipment | 24.074 | 24.132 |
| Intangible assets | 24.655 | 24.475 |
| Investments | 4 | 4 |
| Non current financial assets | 280 | 280 |
| Other non current assets | 1.961 | 1.287 |
| Deferred tax assets | 2.481 | 2.153 |
| CURRENT ASSETS | 74.670 | 72.902 |
| Inventories | 8.483 | 8.852 |
| Cash and cash equivalents | 21.161 | 18.575 |
| Current financial assets | 7.843 | 12.040 |
| Trade receivables | 28.260 | 24.762 |
| Other current assets | 8.394 | 7.831 |
| Tax receivables | 529 | 842 |
| TOTAL ASSETS | 128.125 | 125.233 |
| NET EQUITY | 74.474 | 71.241 |
| --- | --- | --- |
| Share Capital | 1.123 | 1.123 |
| Treasury shares | (5.897) | (5.897) |
| Other Reserves | 76.089 | 56.161 |
| IAS Reserves | (175) | (36) |
| Result of the period | 3.456 | 20.002 |
| Group Equity | 74.596 | 71.353 |
| Third parties equity | (122) | (112) |
| NON CURRENT LIABILITIES | 22.256 | 22.959 |
| Non current financial liabilities | 14.439 | 15.450 |
| Provision for non current risks and charges | 1.687 | 1.841 |
| Provision for employees and directors bene | 6.130 | 5.668 |
| CURRENT LIABILITIES | 31.395 | 31.033 |
| Current financial liabilities | 4.659 | 5.064 |
| Trade payables | 17.516 | 19.897 |
| Other current liabilities | 5.361 | 4.517 |
| Tax payables | 3.859 | 1.555 |
| TOTAL LIABILITIES | 53.651 | 53.992 |
| TOTAL LIABILITIES & EQUITY | 128.125 | 125.233 |
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmacnutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALCERTIFIED
S
SGS
SGS
SGS
FARMINDUSTRIA
ASSOCIATION
MEMBER OF
SGS
INDUSTRIAL
GARAN
CERTIFIED
Cetilar
emarket
with storage
CERTIFIED
PHARMANUTRA
Annex 2
CONSOLIDATED INCOME STATEMENT
| €/1000 | 2026 | 2025 |
|---|---|---|
| TOTAL REVENUES | 33.396 | 26.822 |
| Net revenues | 32.707 | 26.383 |
| Other revenues | 689 | 439 |
| OPERATING EXPENSES | 27.187 | 21.885 |
| Purchases of raw material, cons. and supplies | 1.500 | 1.659 |
| Change in inventories | 754 | (1.469) |
| Expense for services | 22.014 | 19.227 |
| Employee expenses | 2.524 | 2.121 |
| Other operating expenses | 395 | 347 |
| EBITDA | 6.209 | 4.937 |
| Amortization, depreciation and write offs | 947 | 856 |
| EBIT | 5.262 | 4.081 |
| FINANCIAL INCOME/(EXPENSES) BALANCE | - | (28) |
| Financial income | 252 | 134 |
| Financial expenses | (252) | (162) |
| PRE TAX RESULT | 5.262 | 4.053 |
| Income taxes | (1.817) | (1.635) |
| Profit/(loss) of the period | 3.445 | 2.418 |
| Third parties result | (11) | (18) |
| GROUP'S PROFIT/(LOSS) OF THE PERIOD | 3.456 | 2.436 |
| Earning per share (Euro) | 0,36 | 0,25 |
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
| €/1000 | 2026 | 2025 |
|---|---|---|
| PROFIT/(LOSS) OF THE PERIOD | 3.456 | 2.436 |
| Gains (losses) from IAS adoption which will reversed to P&L | ||
| Gains (losses) from IAS adoption which will not be reversed to P&L | (139) | 59 |
| Comprehensive profit/(loss) of the period | 3.317 | 2.495 |
| Di cui: | ||
| Compr. profit/(loss) attributable to minorities | (11) | (18) |
| Net Comp.Profit/(loss) of the group | 3.328 | 2.513 |
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALC ISO 9001
SGS
ISO 14001
FAIRINDUSTRIA
SGS
OHSAS 18001
CERTIFIED
PHARMANUTRA
group
PHARMANUTRA
PHARMANUTRA
CERTIFIED
PHARMANUTRA
AKERN
CERTIFIED
Cetilar
CERTIFIED
PHARMANUTRA
Annex 3
STATEMENT OF CHANGES IN CONSOLIDATED SHAREHOLDERS' EQUITY
| €/1000 | S. C. | Treas. Sh. | Other res. | IAS Res. | Res. of the period | Group equity | Third Part. Cap. and Res. | Third part. res. of the period | Minority interest | Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance as at 1/1/26 | 1.123 | (5.897) | 56.161 | (36) | 20.002 | 71.353 | (27) | (85) | (112) | 71.241 |
| Other changes | (139) | (139) | - | (139) | ||||||
| Allocation of result | 20.002 | (20.002) | - | (85) | 85 | - | - | |||
| Result of the period | 3.456 | 3.456 | (11) | (11) | 3.445 | |||||
| Exchange differences | - | (73) | (73) | - | (73) | |||||
| Balance as at 31/3/26 | 1.123 | (5.897) | 76.089 | (175) | 3.456 | 74.596 | (111) | (11) | (122) | 74.474 |
| €/1000 | S. C. | Treas. Sh. | Other res. | IAS res. | Res. of the per. | Group equity | Third part. Cap. and res. | Third part. res. of the per. | Minority interest | Equity |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Balance as at 1/1/25 | 1.123 | (4.564) | 48.966 | 29 | 16.608 | 62.162 | 30 | (57) | (27) | 62.135 |
| Other changes | (249) | 59 | (190) | - | (190) | |||||
| Allocation of the result | 16.608 | (16.608) | - | (57) | 57 | - | - | |||
| Result of the period | 2.436 | 2.436 | (18) | (18) | 2.418 | |||||
| Exchange differences | - | 48 | 48 | - | 48 | |||||
| Balance as at 31/3/25 | 1.123 | (4.813) | 65.622 | 88 | 2.436 | 64.456 | (27) | (18) | (45) | 64.412 |
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALC ISO 9001
SGS
ISO 14001
FAIRMANUSTRAT
www.fa.gov.in
GOVERNMENT OF INDIA
PHARMANUTRA
SGS
MINISTRY OF
TECHNOLOGY
ARCHAEOLOGY
CETI
emarket
with storage
CERTIFIED
PHARMANUTRA
Annex 4
CONSOLIDATED CASH FLOW
| €/1000- INDIRECT METHOD | 2026 | 2025 |
|---|---|---|
| Net result before minority interests | 3.456 | 2.436 |
| NON MONETARY COST/REVENUES | ||
| Depreciation and write offs | 947 | 856 |
| Allowance to provisions for employee and director benefits | 278 | 242 |
| Third parties result | (11) | (18) |
| CHANGES IN OPERATING ASSETS AND LIABILITIES | ||
| Change in provision for non current risk and charges | (154) | 30 |
| Change in provision for employee and director benefit | 184 | 142 |
| Change in inventories | 369 | (1.494) |
| Change in trade receivables | (3.626) | (1.774) |
| Change in other current assets | (563) | (1.594) |
| Change in tax receivables | 313 | (141) |
| Change in other current liabilities | 852 | 447 |
| Change in trade payables | (2.381) | 982 |
| Change in tax payables | 2.304 | 1.966 |
| CASH FLOW FROM OPERATIONS | 1.968 | 2.080 |
| Investments in intangible, property, plant and equipment | (1.002) | (701) |
| Disposal of intangibles, property, plant and equipment | 53 | |
| Change in other assets | (674) | 880 |
| Change in deferred tax assets | (328) | (223) |
| CASH FLOW FROM INVESTMENTS | (1.951) | (44) |
| Other increase/(decrease) in equity | (212) | 107 |
| Treasury shares purchases | (249) | |
| Dividends distribution | ||
| Financial assets increase | (371) | |
| Financial assets decrease | 4.196 | 7.030 |
| Financial liabilities increase | 5 | 800 |
| Financial liabilities decrease | (1.476) | (1.009) |
| Financial ROU liabilities increase | 151 | 124 |
| Financial ROU liabilities decrease | (95) | (128) |
| CASH FLOW FROM FINANCING | 2.569 | 6.304 |
| TOTAL CHANGE IN CASH AND CASH EQUIVALENTS | 2.586 | 8.340 |
| Cash and cash equivalents at the beginning of the period | 18.575 | 15.494 |
| Cash and cash equivalents at the end of the period | 21.161 | 23.834 |
| CHANGE IN CASH AND CASH EQUIVALENTS | 2.586 | 8.340 |
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmacutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALC ISO 9001
SGS
SGS
FIRE PROTECTIOn
CERTIFIED
SYSTEM CERTIFICATION
001
PHARMANUTRA
group
PHARMANUTRA
PHARMANUTRA
CERTIFIED
AKERN
CERTIFIED
Cetilar
CERTIFIED
PHARMANUTRA
Pharmanutra S.p.A.
Founded in 2003 in Pisa by Andrea and Roberto Lacorte, Pharmanutra is the holding company of an international Group engaged in the research, development, and commercialization of nutritional supplements, medical devices, and patented raw materials. A leader in iron-based supplements through its Sucrosomial® Technology (SiderAL® and Apportal®), and an emerging player in medical devices for mobility (Cetilar®), the Group internally manages the entire value chain and holds a solid portfolio of patents, brands, and clinical evidence.
Pharmanutra operates in over 80 countries, with subsidiaries in the USA and Spain, and also includes Akern S.r.l. (bioimpedance analysis) and Athletica Cetilar S.r.l. (sports medicine)
pharmanutragroup.com
pharmanutra.it
For further information:
Pharmanutra S.p.A.
Via Campodavela 1 - 56122 Pisa
Tel. +39 050 7846500
Simona Del Re
[email protected]
[email protected]
Internal Press Office
[email protected]
Press Office - Spriano Communication & Partners
Via Santa Radegonda, 16 - 20121 Milano
Tel. +39 02 83635708
Matteo Russo
[email protected]
Cristina Tronconi
[email protected]
Pharmanutra S.p.A.
Via Campodavela, 1 - 56122 Pisa | +39 050 7846500
pharmanutragroup.com | pharmanutra.it | [email protected] | [email protected]
C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N | Cap.Soc. € 1.123.097,70 I.V. | REA 146259
ALCERTIFIED
ISO 9001
S
FORM 9850:2008 UNI EN ISO 45001:2008
PAYMENTS IN THE EUROPEAN THEATER OF OPERATIONS
PARLIAMENT
PHARMANUTRA
ALCERTIFIED
ACKER
GROUP
PHARMANUTRA
ALCERTIFIED
PHARMANUTRA
ALCERTIFIED
Cetilar
| Fine Comunicato n.20106-20-2026 | Numero di Pagine: 13 |
|---|---|